Lanreotid Zentiva

Lanreotide, the active ingredient in Lanreotid Zentiva, is a somatostatin analog presented as an injectable solution for subcutaneous use. It reduces excess growth hormone in acromegaly and controls hormone‑secreting neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics to ensure product integrity during global distribution. Clients benefit from reliable supply, technical support and regulatory documentation.

Lanreotide is used in endocrine disorders that involve excess hormone secretion. Acromegaly: reduces growth hormone secretion, normalizes IGF‑1 levels and improves clinical symptoms such as enlarged hands, facial features and joint pain. Neuroendocrine tumors: controls hormone secretion from functional tumors, alleviating carcinoid syndrome symptoms like flushing and diarrhea and may slow tumor progression. Carcinoid syndrome: specifically reduces flushing, bronchospasm and diarrhoea associated with serotonin‑producing neuroendocrine tumors. Functional pancreatic neuroendocrine tumors: decreases excessive hormone output, aiding control of symptoms such as hypoglycemia or gastric hypersecretion.

Lanreotide may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site reactions: pain, erythema, induration or swelling at the injection site. - Gastrointestinal disturbances: nausea, abdominal pain, diarrhea or constipation. - Gallbladder abnormalities: biliary sludge, gallstones or cholecystitis. - Hyperglycemia: elevated fasting glucose or HbA1c levels.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with raised pancreatic enzymes. - Severe allergic reactions: anaphylaxis, urticaria, angioedema or bronchospasm. - Cardiac conduction disturbances: bradycardia, heart block or other arrhythmias.

When prescribing Lanreotide, clinicians should consider several precautionary measures to ensure safe use. - Assess baseline hormone levels: evaluate growth hormone and IGF‑1 before initiating therapy. - Monitor glucose metabolism: check fasting glucose and HbA1c periodically during treatment. - Evaluate gallbladder status: perform ultrasound in patients with a history of gallstones or biliary disease. - Review concomitant medications: avoid drugs that may exacerbate hyperglycemia or affect gastrointestinal motility. - Adjust in organ impairment: use caution and consider dose modification in severe renal or hepatic dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide plasma concentrations, raising risk of adverse effects. - Somatostatin analog antagonists: can diminish the therapeutic effect of lanreotide.

Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: lanreotide may affect glucose control, requiring dose adjustments. - Insulin therapy: monitor blood glucose closely as lanreotide can alter insulin requirements. - Medications that prolong QT interval: co‑administration may increase risk of cardiac arrhythmias. - Octreotide: concurrent use may lead to additive hormonal suppression.